Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05737472
Other study ID # 1000079230
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 14, 2022
Est. completion date August 23, 2023

Study information

Verified date April 2024
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a proof-of-concept trial that aims to compare the efficacy of an 8-week treatment with higher-protein-Ready-to-Use Therapeutic Foods (RUTF) with standard RUTF in improving levels of markers of growths, height, nutritional recovery, and lean mass deposition among children with severe wasting. The study will also assess the safety and acceptability of the high-protein RUTF in comparison to the standard RUTF. The study will be conducted at four outpatient therapeutic programs in the Blantyre district of Malawi.


Description:

RUTF has successfully promoted recovery from severe wasting and widened treatment coverage. However, RUTF does not sufficiently promote linear growth, leaving many survivors of severe wasting at risk of persistent stunting. Stunting is associated with long-term effects like poor child development and an increased risk of non-communicable diseases in adults. High protein quantity and quality are known to stimulate linear growth; however, an RUTF with a higher protein quantity and quality than the standard RUTF has yet to be tested. The investigators hypothesize that the suboptimal linear growth in children surviving severe malnutrition can be improved by increasing the protein quantity and quality in the standard RUTF formulation. The investigators have designed a high protein quantity and quality RUTF that will be tested in a proof-of-concept quadruple-blind randomised controlled trial study design. The trial aims to compare the efficacy of higher-protein-RUTF and standard RUTF in improving markers of linear growth among 6-23 months old children with severe wasting. Children aged 6-23 months newly enrolled in outpatient treatment programs for severe wasting and without medical complications are eligible. They will be assigned to either increased protein RUTF or standard RUTF for eight weeks. The primary outcome is a change in insulin-like growth factor-1 (IGF- 1) after four weeks of treatment. IGF-1 is a hormone that is mechanistically linked with growth. Secondary outcomes include ponderal and linear growth changes from baseline measured at eight weeks and plasma amino acid profile at four weeks. Other secondary outcomes are the acceptability and safety of high protein RUTF compared to standard RUTF. These findings will help to determine the optimal protein composition of RUTF to promote linear growth when treating severe wasting in children.


Recruitment information / eligibility

Status Completed
Enrollment 128
Est. completion date August 23, 2023
Est. primary completion date July 26, 2023
Accepts healthy volunteers No
Gender All
Age group 6 Months to 23 Months
Eligibility Inclusion Criteria: - Infants 6-23 months of age with severe wasting at OTP admission according to the WHO criteria: WHZ below -3 or MUAC below 115mm. - Parent or guardian is able and available to consent - Children who are able to feed orally in the usual state of health - The primary caregiver plans to stay in the study area during the duration of the study. Exclusion Criteria: - Children with medical complications as per the CMAM guidelines (lack of appetite, severe oedematous malnutrition, acute infections) - mild and moderate nutritional oedema - Children with a known terminal illness (e.g. cancer), cerebral palsy (CP), tuberculosis (TB,) HIV infected or exposed - Children who had SAM in the last 8 weeks, i.e., SAM relapses in the last 8 weeks - Children admitted to any NRU due to complicated SAM in the previous 4 weeks will also be excluded - Children whose caregivers refuse to give consent or whose primary givers are not available to give consent - Children who were previously enrolled in this trial or currently enrolled in this trial whose sibling has also been enrolled in the study - Children with known intolerance or allergy to high protein diets will be excluded as well as known intolerance or allergy to milk/lactose

Study Design


Intervention

Dietary Supplement:
High-protein RUTF
The high-protein RUTF is isocaloric to the standard RUTF. To have a higher protein quantity and quality, the recipe has greater proportions of milk powder plus whey protein and vegetable oil. A total of 15% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS )of the high protein, RUTF is 1.18 which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 1.19
Standard RUTF
The standard RUTF was manufactured according to WHO recommendations, with at least 50% of protein-sourced dairy, mainly skim milk. A total of 10% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS) of the standard RUTF is 0.76, which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 0.86.

Locations

Country Name City State
Malawi Ndirande, Mbayani, Bangwe, Limbe and Bangwe health centres Blantyre

Sponsors (5)

Lead Sponsor Collaborator
The Hospital for Sick Children Friends of Sick Children, Malawi, Ministry of Health, Malawi, Nutriset, Schlumberger Foundation

Country where clinical trial is conducted

Malawi, 

References & Publications (2)

Potani I, Spiegel-Feld C, Brixi G, Bendabenda J, Siegfried N, Bandsma RHJ, Briend A, Daniel AI. Ready-to-Use Therapeutic Food (RUTF) Containing Low or No Dairy Compared to Standard RUTF for Children with Severe Acute Malnutrition: A Systematic Review and Meta-Analysis. Adv Nutr. 2021 Oct 1;12(5):1930-1943. doi: 10.1093/advances/nmab027. — View Citation

Shivakumar N, Jackson AA, Courtney-Martin G, Elango R, Ghosh S, Hodgkinson S, Xipsiti M, Lee WTK, Kurpad AV, Tome D. Protein Quality Assessment of Follow-up Formula for Young Children and Ready-to-Use Therapeutic Foods: Recommendations by the FAO Expert Working Group in 2017. J Nutr. 2020 Feb 1;150(2):195-201. doi: 10.1093/jn/nxz250. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in plasma IGF-1 To assess the efficacy of high-protein-RUTF with higher protein quality and quantity compared to standard RUTF in increasing circulating IGF- 1 in 6-23-month-old children with severe wasting. 4 weeks
Secondary Changes in height for age z score To assess the efficacy of high-protein-RUTF with higher protein quality and quantity compared to standard RUTF in improving change in height-for-age z score. 8 weeks
Secondary Changes in weight for age z score To assess the efficacy of high-protein-RUTF with higher protein quality and quantity compared to standard RUTF in improving change in weight for age z score 8 weeks
Secondary Changes in weight for height z score To assess the efficacy of high-protein-RUTF with higher protein quality and quantity compared to standard RUTF in improving change in weight for height z score 8 weeks
Secondary Changes in knee heel length To assess the efficacy of high-protein-RUTF with higher protein quality and quantity compared to standard RUTF in improving change in knee heel length 8 weeks
Secondary Changes in plasma essential amino acid profile leucine, threonine and tryptophan To assess the efficacy of high-protein-RUTF with higher protein quality and quantity compared to standard RUTF in improving plasma essential amino acids: leucine, threonine and tryptophan 4 weeks
Secondary Changes in IGFBP3 To assess the efficacy of high-protein-RUTF with higher protein quality and quantity compared to standard RUTF in increasing IGFFBP3 4 weeks
Secondary Changes in fat free mass accretion • To assess the efficacy of high-protein-RUTF with higher protein quality and quantity compared to standard RUTF in improving fat free mass accretions (kg/m2) using bioelectrical impedance and skinfold thickness 8 weeks
Secondary Changes in fat mass accretion • To assess the efficacy of high-protein-RUTF with higher protein quality and quantity compared to standard RUTF in improving fat mass accretion (kg/m2) using bio-electrical impedance assessment and skinfold thickness 8 weeks
Secondary Acceptability of high-protein RUTF • To assess acceptability of the high protein RUTF formulation compared to standard RUTF among children with severe wasting using an adaptation of action against hunger RUTF apettite test 4
Secondary Acceptability of high-protein RUTF • To assess acceptability of the high protein RUTF formulation compared to standard RUTF among children with severe wasting by observing RUTF intake at participant homes for 5 hours at a single time point 4
Secondary Compliance of high-protein RUTF • To assess compliance of the high protein RUTF formulation compared to standard RUTF among children with severe wasting by conducting in-depth interviews with the caregivers 4
Secondary Safety of the high protein RUTF formulation:adverse events To assess the safety of high-protein-RUTF compared to standard RUTF by recording adverse events (defined as any untoward event including morbidity reported by the participant or detected by the investigator) 8 weeks
Secondary Safety of the high protein RUTF formulation: severe adverse events To assess the safety of high-protein-RUTF compared to standard RUTF by recording adverse events (defined as any life threatening event reported by the participant or detected by the investigator) 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT03360877 - Prevention of Nosocomial Infections (CleanKids) N/A
Completed NCT04715204 - Gastrointestinal Tolerance of Under-five Children With Severe Acute Malnutrition to ONS Compared to F-75/F-100 N/A
Not yet recruiting NCT06061484 - Modified Dosage for Severe Acute Malnutrition N/A
Not yet recruiting NCT06038071 - Family Mid-Upper Arm Circumference (MUAC) Follow-up After Recovery From Acute Malnutrition (MODAM-fMUAC) N/A
Completed NCT03666572 - Pilot of a Prebiotic and Probiotic Trial in Young Infants With Severe Acute Malnutrition Phase 2
Completed NCT05020847 - Effectiveness of Alternative Diets During the Stabilization Phase on Children With Complicated SAM N/A
Completed NCT05015257 - Effectiveness of Four Transition Dietary Regimens in the Hospital Management of Children With Kwashiorkor. N/A
Recruiting NCT06123390 - Evaluating RISQ System Implementation in Acutely Malnourished Children in Chad (CRIMSON) N/A
Completed NCT03370003 - Non-routine Use of Antibiotics (Amoxi-light)
Completed NCT03303131 - SAM: Discharge Based on the Use of a MUAC-based Criterion to N/A
Recruiting NCT06002438 - Eggs for Gut Health N/A
Terminated NCT05473234 - Azithromycin for Severe Acute Malnutrition in CMAM, Nigeria Phase 3
Completed NCT01613547 - The Effect of Routine Antibiotic Use in the Outpatient Treatment of Severely Malnourished Children Without Complications N/A
Completed NCT01331044 - Ready to Use Therapeutic Food (RUTF) in Severe Malnourished Children N/A
Completed NCT03094247 - Feeding Malnourished Children Different Types of Fatty Acids to Promote Neurocognitive Development N/A
Recruiting NCT04240990 - Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition N/A
Completed NCT01958905 - Efficacy and Bio-availability of Artemether-Lumefantrine in Severely Malnourished Children N/A
Completed NCT03716115 - Therapeutic Approaches to Malnutrition Enteropathy Phase 2
Completed NCT01593969 - A Trial of n-3 PUFA-Enriched Ready to Use Therapeutic Food for Childhood Severe Malnutrition Phase 2
Completed NCT05891457 - Changes in Nerve Electro Physiologic Properties in Children Before and After Correction of Malnutrition N/A